Webster Bank N. A. trimmed its position in Bristol-Myers Squibb Co (NYSE:BMY) by 1.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 84,851 shares of the biopharmaceutical company’s stock after selling 1,054 shares during the period. Webster Bank N. A.’s holdings in Bristol-Myers Squibb were worth $5,200,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of the stock. Bredin Investment LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter worth $1,937,000. Howard Capital Management grew its stake in Bristol-Myers Squibb by 0.5% in the fourth quarter. Howard Capital Management now owns 176,010 shares of the biopharmaceutical company’s stock worth $10,786,000 after purchasing an additional 804 shares during the period. Cornerstone Financial Partners LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter worth $260,000. Cornerstone Investment Partners LLC grew its stake in Bristol-Myers Squibb by 100.0% in the fourth quarter. Cornerstone Investment Partners LLC now owns 19,168 shares of the biopharmaceutical company’s stock worth $1,175,000 after purchasing an additional 9,584 shares during the period. Finally, Patten & Patten Inc. TN grew its stake in Bristol-Myers Squibb by 5.5% in the fourth quarter. Patten & Patten Inc. TN now owns 176,814 shares of the biopharmaceutical company’s stock worth $10,835,000 after purchasing an additional 9,251 shares during the period. 69.82% of the stock is currently owned by institutional investors.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $67.35 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05. The company has a market capitalization of $112,582.92, a price-to-earnings ratio of 22.91, a P/E/G ratio of 2.14 and a beta of 1.09.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same period last year, the firm posted $0.63 earnings per share. Bristol-Myers Squibb’s revenue was up 3.9% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were given a dividend of $0.40 per share. The ex-dividend date was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.38%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.
In related news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
BMY has been the topic of several recent research reports. Credit Suisse Group reaffirmed a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, January 19th. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price on the stock. in a research note on Thursday, February 8th. Finally, BMO Capital Markets cut their target price on Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $66.73.
TRADEMARK VIOLATION WARNING: “Webster Bank N. A. Sells 1,054 Shares of Bristol-Myers Squibb Co (BMY)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/21/webster-bank-n-a-sells-1054-shares-of-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.